logo
ProjectOngoing

Casting light on HOst-cytomegaloviRUs interaction in Solid organ transplantation

The status, timeline and source of this project. A free account opens every field.

Source: EU Funding & Tenders Portal

"Solid organ transplantation (SOT) is the treatment of choice for end-stage organ failure but the immunosuppressive drugs used to prevent graft rejection expose to an increased risk of opportunistic infections among which CMV disease leads to the most frequent morbidity and even mortality. HORUS project gathers solid-organ transplantation experts, computational data scientists, virologists and imm

Status
Under Construction
Location
France
Updated
22 Jul 2026
Source
EU Funding & Tenders Portal

ConstructChat

Ask ConstructChat about Casting light on HOst-cytomegaloviRUs interaction in Solid organ transplantation

Pick a question to edit it, or write your own.

First answer free · no account

I am a

Project Information FAQ

Project Information

3 Q
The project “Casting light on HOst-cytomegaloviRUs interaction in Solid organ transplantation” is an infrastructure initiative, located in France, Czechia, Germany, Belgium, Netherlands, Italy, Spain. Taiyo aggregates data on it from EU Funding & Tenders Portal.

Participants

Not available for this record.

Status

Original status

ongoing

Taiyo status

Under Construction

Taiyo last update

2026-07-22

Contact

Not available for this record.

Description

Description

"Solid organ transplantation (SOT) is the treatment of choice for end-stage organ failure but the immunosuppressive drugs used to prevent graft rejection expose to an increased risk of opportunistic infections among which CMV disease leads to the most frequent morbidity and even mortality. HORUS project gathers solid-organ transplantation experts, computational data scientists, virologists and immunologists in a fully operating European network including 25 partners. HORUS ambitious but realistic goals is to improve our understanding of CMV/host interactions in the context of immunosuppression, with a particular focus on i) the characterization of signatures associated with the control of CMV replication after transplantation, ii) the characterization of signatures associated with the evolution toward a difficult-to-treat CMV disease and poor outcome during CMV replication, iii) the discovery of new specific immunomodulatory molecules promoting CMV control while maintaining prevention of acute rejection. HORUS includes the constitution of the first European SOT recipient longitudinal cohort. In a sub- “HORUS-exploratory cohort”, we will perform a deep investigation of viral, clinical and immunological characteristics. Combining those parameters will provide a signature early after transplantation to predict the risk of developing CMV infection and a signature at day 0 of infection to predict the risk of CMV disease severity. This signature will next be validated retrospectively on the whole cohort and prospectively in a “proof-of-concept"" study. Moreover, HORUS will include functional in vitro and mice models to understand the mechanisms of lymphocyte response to CMV and provide innovative methods to increase CMV-specific immunity. Altogether, HORUS will lead to personalized clinical prevention and treatment of CMV disease and to improvement of patient outcomes."

Location

Country

France

Source

Source

EU Funding & Tenders Portal

URL

More Details

Record type

Project

Article published date

2025-12-15

More on this project

Research

Free account

View all details

You are reading the public part. A free account opens the rest:

  • Every detail on this project
  • News and media coverage
  • Technical research
View all details

Free account · no card · lands you back on this project